Skip to main content
Premium Trial:

Request an Annual Quote

Matthew Watson, David Baunoch, David Cooper, Mark Gardner, Iain Mattaj


Matthew Watson has been named chief executive officer of CombiMatrix Molecular Diagnostics, a new subsidiary of Acacia's CombiMatrix group, the company said this week.

Watson previously served as vice president of laboratory operations at US Labs, now Laboratory Corporation of America. He also held positions at Nichols Institute, now Quest Diagnostics, and Specialty Labs.

Watson holds a BS in biology from Eastern Connecticut State University and an MBA from The University of Hartford.

CombiMatrix Molecular Diagnostics also named David Baunoch president and chief operating officer. Baunoch previously served as vice president of R&D at US Labs. He also worked at Ventana Medical Systems, where he served as a product manager and in product development.

He also held various positions in the department of pathology at the University of Chicago. Baunoch received his PhD in microbiology and molecular genetics at Wayne State University.

David Cooper has been named senior vice president, finance, and treasurer at Agilent Technologies. Most recently, he was CFO of QRS, a collaborative services and software provider.

Mark Gardner has been promoted to chief marketing officer of Invitrogen, the company said this week. Most recently, he was Invitrogen's vice president of commercial marketing. Gardner holds a BS from the United States Naval Academy, an MA in international relations from Georgetown University, and an MBA from the Wharton School of Business at the University of Pennsylvania.

Iain Mattaj took office as director-general of the European Molecular Biology Laboratory on May 1, EMBL said this week. For the last five years, he was EMBL's scientific director.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.